Loading
A phase 2 trial of Ponatinib in chronic myeloid leukaemia and acute lymphoblastic leukaemia, run by Otsuka Beijing Research Institute, active and no longer recruiting.
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation is a phase 2 interventional study registered as NCT04233346 by Otsuka Beijing Research Institute, with 93 participants enrolled, started 2020-07-09 and due to reach its primary completion in 2022-07-22. Interventions recorded: Ponatinib 30mg OD and Ponatinib 45mg OD.
Shares Ponatinib, Chronic myeloid leukaemia (CML), Acute lymphoblastic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic myeloid leukaemia, accelerated and blast phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic myeloid leukaemia, accelerated and blast phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Otsuka Pharmaceutical and the tag pipeline.
Shares Chronic myeloid leukaemia, accelerated and blast phase, Chronic myeloid leukaemia (CML), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Chronic myeloid leukaemia, accelerated and blast phase, Chronic myeloid leukaemia (CML), Acute lymphoblastic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic myeloid leukaemia (CML), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors and the tag pipeline.